Study of the Cardiometabolic Effects of Obesity Pharmacotherapy

Phase 4 Unknown 40 enrolled National and Kapodistrian University of Athens Athens Medical Center · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The aim of the present study is to compare the efficacy of liraglutide vs. naltrexone/bupropion on metabolic and cardiovascular risk markers, weight loss, as well as the postprandial secretion of gastrointestinal hormones involved in hunger and satiety, after a test meal. The study will include 40 patients, who will further be divided into two treatment groups (20 patients on liraglutide vs. 20 patients on naltrexone/bupropion). The patients will be examined at baseline, 3 and 6 months after the treatment initiation.

Timeline

Start: 2020-09-08
Primary completion: 2022-09-30
Completion: 2023-05-30

Publications

Stefanakis K, Kokkinos A, Simati S, Argyrakopoulou G, Konstantinidou SK, Kouvari M, Kumar A, Kalra B, Mantzoros CS. Circulating levels of all proglucagon-derived peptides are differentially regulated postprandially by obesity status and in response to high-fat meals vs. high-carbohydrate meals. Clin Nutr. 2023 Aug;42(8):1369-1378. doi: 10.1016/j.clnu.2023.06.026. Epub 2023 Jun 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Bupropion	Small molecule	360 mg	Oral
Comparator	Liraglutide	Peptide	3 mg	Subcutaneous
Comparator	Naltrexone	Small molecule	32 mg	Oral

Study of the Cardiometabolic Effects of Obesity Pharmacotherapy

Summary

Timeline

Publications

Drugs

Indications